Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[68Ga]P15-041 PET/CT in prostate cancer bone metastases
NCT02826382Phase 1Completed
- Sponsor
- Five Eleven Pharma, Inc.
- Start
- Sep 2016
- Primary completion
- Dec 2022
- Modality
- PET/CT (Positron Emission Tomography/Computed Tomography)
- Countries
- 1
01
Overview
Phase 1, open-label trial of [68Ga]Ga-P15-041 in prostate cancer (PCa) (2 arms), sponsored by Five Eleven Pharma, Inc. Primary endpoints: Time course of uptake of [68Ga]P15-041 in bone metastases and Time course of whole body distribution of [68Ga]P15-041. Started Sep 2016; status: completed.
02
Drugs
[68Ga]Ga-P15-041
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02826382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02826382.